Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call Transcript

Raul Rodriguez : But more to come, I think go. And I think it’s very early. It’s hard. It’s hard to be specific at this point. We’re just getting data in and evaluating it.

Kalpit Patel: Okay. And are you seeing, again, this might be early, but are you seeing any combination based may be off label uses with azacitidine and then to your earlier setting or do you not have the data for that?

Raul Rodriguez : We don’t have data for what they’ve – they’re using it with. It’s – and we would only have that for those patients who go through our RIGE. ONECARE Hub, for others we just get the diagnosis of AML. So, we don’t have, if clinicians are using it with HMAs, it’s specifically azacitidine. But we suspect that that probably is going on out there. It’s just difficult for us to see in any of our data.

Kalpit Patel: Okay. Okay. Got it. And then one last question on fostamatinib for chronic graft-versus-host disease. We have been hearing on our end that there’s additional interest from at least the KOL community for this program. So, I’m curious if there is any progress on that and whether you have decided if this might be 2023 event for that opportunity?

Raul Rodriguez : Yeah, very good question and thank you for your interest in a good calling yesterday and what was very – or a couple days ago. We are very interested in GVHD. We’re looking at that area very closely. As I said earlier, we are speaking with KOLs in the area doing some market research, speaking with regulators, as well because we’d like to have a nice package when we come to you and say here’s what we want to do for this indication or that indication of which GVHD is one of those. So I’ll look forward to later this year coming back to you with specifics, here’s what we want to do across these indications. And so we could share that with you at that point in much more detail. But we are doing a fair amount of work in this area. We think it’s pretty exciting.

Kalpit Patel: Okay, fantastic. Thank you very much.

Operator: There are no further questions in the queue. I would like to hand the call back to Mr. Rodriguez for closing remarks.

Raul Rodriguez : So, thank you, everyone. I’d like to thank you for joining the call and you’re interested in Rigel. I would like to also thank our employees for their continued commitment to improving the lives of patients. And we look forward to updating you on future calls. This quarter was, I think a fantastic quarter, a great start to the year. The rest of the year we have, I think equally exciting things to update you on across a range of different products and indications. So, very much look forward to doing that as well in the not that distant future. So, thank you very much.

Operator: Ladies and gentlemen this does conclude today’s teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.